ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations

Heart failure patients vaccinated against influenza are at a significantly lower risk of dying, both during flu season and outside of it.

Patients with heart failure vaccinated had a 48% lower risk of death during influenza season and a 21% lower risk during the rest of the year.

Dr. Fukuta, lead investigator in this study, explained that flu vaccination of heart failure patients in Japan is not formally recommended. Larger-scale and adequately powered randomized controlled trials, such as INVESTED, will provide a definitive answer.

At the moment, with some inconsistent results, we must settle for this meta-analysis led by Dr. Fukuta, which includes 5 observational studies involving a total of 78,882 patients with heart failure. The age of patients ranged from 64 to 75 years old, and study follow-up was between 1 and 4 years.


Read also: ACC 2018 | Risk of MI in Non-Cardiac Surgeries.


There are physiopathologic reasons supporting vaccination, such as the fact that respiratory infections (including influenza) are the precipitating cause of heart failure and are associated with increased mortality. If vaccination reduces the incidence and/or severity of these respiratory infections, it will prevent heart failure exacerbations, hospitalization, and associated mortality.

Furthermore, vaccination reduces the risk of cardiovascular events, including infarction and unstable angina, in patients with coronary artery disease. There are studies showing a sixfold higher risk of infarction in the week after a flu diagnosis. In such cases, physiopathology is probably related to inflammation.

Original title: The Effect of Influenza Vaccination on Mortality and Hospitalization in Patients with Heart Failure: A Meta-Analysis.

Presenter: Fukuta H.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...

J-Valve for Chronic AR: 30-Day Outcomes of Transfemoral Valve J-Valve in Chronic Aortic Regurgitation

Chronic aortic regurgitation (AR) poses a significant challenge as far as transcatheter alternatives go due to the absence of calcification and a suitable anchoring...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...